San Diego, Ca., USA - March 8, 2010, San Diego, Ca., USA - Afraxis, a biotechnology company, announced the appointment of David Campbell as chief scientific officer and Carmine Stengone as vice president, corporate development.
Article continues below
Prior to Afraxis, Dr. Campbell served as a member of the Phenomix Corporation executive team since 2003. Most recently he was an executive officer and senior vice president, discovery and development, with responsibility for all drug discovery and development through early clinical development to proof of concept in humans.
Dr. Campbell was the senior vice president of chemical sciences at ActivX Biosciences from 2001 to 2003, where he directed the company's internal drug discovery programs as well as the development of ActivX's activity-based chemical probes. Dr. Campbell was director of discovery chemistry at Bayer Corporation where he directed the research efforts of the 41-scientist group discovering and optimizing drugs in the cancer, obesity, osteoporosis, and diabetes therapeutic areas.
Dr. Campbell began his career at Affymax Research Institute, a combinatorial chemistry company that was creating novel technologies and strategies to facilitate the identification and optimization of compounds for the treatment of cancer and immune-mediated diseases.
Dr. Campbell holds three sole-authored and fifteen jointly authored patents, and has co-authored 30 original papers. He conducted post-doctoral studies at the University of California, Berkeley, after receiving a Ph.D. in organic chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College.
Mr. Stengone has more than 10 years of experience in the pharmaceutical and biotechnology industries, including positions in finance, strategic planning, business development, alliance management, market research and venture funding.
Prior to joining Afraxis, he was with Phenomix Corporation from 2006 to 2010, where he was responsible for strategic collaborations and licensing agreements. He was also a member of the Phenomix executive management team as the senior director of business development.
Mr. Stengone served as senior manager, business development and strategic marketing for Anadys Pharmaceuticals, Inc. from 2004 to 2006. Prior to that, Mr. Stengone held a variety of positions at Johnson & Johnson Pharmaceutical Research and Development. ■